ASXL1 and acute myeloid leukemia: AML harboring TP53, RUNX1, ASXL1, and RAS mutations, found in the adverse-risk category, exhibits a higher immune effector dysfunction (IED172) score and an IFNγ signature, the latter being associated with a positive response to azacytidine (AZA) + pembrolizumab [75].